Bristol-Myers beats Q2 earnings and revenue estimates, driven by growth drugs, while raising its full-year 2026 sales and profit outlook.
Bristol-Myers Squibb Co.
(NYSE:BMY) shares are up on Thursday as the company reported its second-quarter financial results for 2026. • Bristol-Myers Squibb stock is showing upward movement.
Why are BMY shares climbing?
The U.S. large pharma company reported adjusted earnings of $2.04, beating the Wall Street estimate of $1.59.
Sales of $12.973 billion increased 6%, surpassing the consensus of $11.745 billion.
BMY to release Q2 earnings on 7/30. Analysts expect $1.60 EPS and $11.74B revenue. Dividend yield is 3.96%. To earn $500 monthly,…
Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the world's 4th-largest drugmaker.
Bristol Myers Squibb Announces Dividend
The stock has been a major outperformer lately amid the weakness in tech stocks.
Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.
Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall…
